ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Concalls
Every earnings call, live and summarised
Earnings calls
Every Suraksha Diagnostic earnings call we streamed: the live audio and our summary of what management said.
Suraksha delivered strong high double-digit growth in Q2 FY27, crossing the ₹100 crore revenue milestone. Expansion beyond West Bengal is progressing well, though seasonal festive dips are expected in Q3.
Suraksha delivered strong high double-digit growth in Q2 FY27, crossing the ₹100 crore revenue milestone. Expansion beyond West Bengal is progressing well, though seasonal festive dips are expected in Q3.
Management guides for 15-18% revenue growth for FY27 with steady 34-35% EBITDA margins.
Suraksha Diagnostic reported a robust Q1 FY27 with 21% revenue growth and 40% PAT growth, driven by expansion in West Bengal and Jharkhand and a high-growth genomics segment.
Suraksha Diagnostic Limited concluded FY26 with 23.1% revenue growth to INR 3104M. Strategy shifts towards specialized genomics and multi-state expansion into Bihar, Tripura, and Jharkhand.
Suraksha Diagnostic reported robust FY26 revenue growth of 23.1% YoY, driven by aggressive regional expansion and a shift toward high-value genomic and specialized radiology testing.
Suraksha Diagnostic reported robust FY26 results with 23% revenue growth and 16% EBITDA growth, driven by core diagnostic momentum and expansion in Eastern India.
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.